Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boulle-SEI awards: A collaboration between the Spanish Society for immunology, the University of Alicante and the Jean Boulle Group to honor the Balmis Expedition

TY - JOUR

T1 - Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boulle-SEI awards

T2 - A collaboration between the Spanish Society for immunology, the University of Alicante and the Jean Boulle Group to honor the Balmis Expedition

AU - Ochando, Jordi

AU - Camara, Carmen

AU - Durham, Leighton

AU - Sempere, Jose Miguel

AU - Lopez-Hoyos, Marcos

N1 - Funding Information: To discuss about national networks research networks, Jesus Frias , Director of the Spanish Clinical Research Network (SCReN), which is funded by the Instituto de Salud Carlos III and the European Regional Development Fund ( ERDF ) to support clinical investigations, highlighted the advantages of collaborative, non-profit network structures with a national scope. SCReN ( https://scren.eu ) is a clinical research platform made up of a set of clinical research units and their capacities to provide scientific-technical services through infrastructures and professionals belonging to different institutions nationwide. Its mission is to guarantee the provision of transversal services to support the development of research projects included in clinical investigations and clinical trials and transfer of knowledge to the national health system. This networked structure, made up of 34 support units distributed throughout the country, has more than 100 people on staff with different profiles, which are responsible for the support of research teams in the implementation, development and monitoring more than 200 clinical research projects. One of the most recent projects is the CombiVacS study: “Immunogenicity and reactogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1S: initial results of a randomised phase 2 clinical trial (CombiVacS)”, a phase 2, open-label, randomised, controlled clinical trial on adults vaccinated with a single dose of ChAdOx1-S (AstraZeneca) who received a second dose of BNT162b2 (Pfizer). Results with data on 7-day reactogenicity and 14-day anti-spike IgG response, antibodies functionality and cellular immune response demonstrated safety and immunogenicity of heterologous vaccination ( Borobia et al., 2021 ). Funding Information: To discuss about national networks research networks, Jesus Frias, Director of the Spanish Clinical Research Network (SCReN), which is funded by the Instituto de Salud Carlos III and the European Regional Development Fund (ERDF) to support clinical investigations, highlighted the advantages of collaborative, non-profit network structures with a national scope. SCReN (https://scren.eu) is a clinical research platform made up of a set of clinical research units and their capacities to provide scientific-technical services through infrastructures and professionals belonging to different institutions nationwide. Its mission is to guarantee the provision of transversal services to support the development of research projects included in clinical investigations and clinical trials and transfer of knowledge to the national health system. This networked structure, made up of 34 support units distributed throughout the country, has more than 100 people on staff with different profiles, which are responsible for the support of research teams in the implementation, development and monitoring more than 200 clinical research projects. One of the most recent projects is the CombiVacS study: “Immunogenicity and reactogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1S: initial results of a randomised phase 2 clinical trial (CombiVacS)”, a phase 2, open-label, randomised, controlled clinical trial on adults vaccinated with a single dose of ChAdOx1-S (AstraZeneca) who received a second dose of BNT162b2 (Pfizer). Results with data on 7-day reactogenicity and 14-day anti-spike IgG response, antibodies functionality and cellular immune response demonstrated safety and immunogenicity of heterologous vaccination (Borobia et al., 2021).The jury of the awards are international scientist of accredited prestige appointed by the SEI and includes: Sir Marc Feldmann, Professor at the University of Oxford; Maria Neira: Director of Department of Environment, Climate Change and Health at the World Health Organization (WHO); Gabriel Nunez, Endowed Professor of Pathology at the University of Michigan; Laurance Zitvogel, Group Leader of Tumour immunology and immunotherapy of cancer at Institut Gustave Roussy; Jose Villadangos, Professor in the Department of Microbiology and Immunology at the University of Melbourne; Jacques Banchereau, Professor and Director of Immunological Sciences at The Jackson Laboratory for Genomic Medicine; Kathryn Wood, Professor of Immunology in the Nuffield Department of Surgical Sciences at the University of Oxford; Alain Fischer, Director of the Pediatric Immunology Unit at Hôpital Necker-Enfants malades, Padmanee Sharma, Professor of Genitourinary Medical Oncology and Immunology at University of Texas MD Anderson Cancer Center; and James Allison, Professor and Chair of the Department of Immunology at the University of Texas MD Anderson Cancer Center.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85133270351&partnerID=8YFLogxK

U2 - 10.1016/j.crimmu.2022.06.001

DO - 10.1016/j.crimmu.2022.06.001

M3 - Review article

AN - SCOPUS:85133270351

VL - 3

SP - 136

EP - 145

JO - Current Research in Immunology

JF - Current Research in Immunology

SN - 2590-2555

ER -